Subscribe to the newsletterForward | Contact |   November 2013
10/22/2013 - CELLPAT project obtains public funding from the Single Inter - Ministry Fund

Following its accreditation by Lyonbiopole, the CELLPAT project for modeling and control of online bioprocesses in bioreactor adapted to animal cells, was selected by the DGCIS in the 16th call for project of the Single Inter - Ministry Fund. Since 2005, Lyonbiopole has accredited 135 multi-partner R&D projects for a total R&D investment of € 671 million of which € 269 million of public aid were obtained.
Contact: Claudia Chagneau, R&D Projects Manager -

Learn more

10/11/2013 - Great success for the 7th edition of Lyonbiopole's Partnering Days

Lyonbiopole's Partnering days represent an annual opportunity for members to meet and exchange. They were held October 11, 2013 at Espace Ouest Lyonnais. With more than 300 participants, this 7th edition allowed to expand the clusters topics. 17 round tables were held on themes such as inflammation and neurological diseases, cardiovascular diseases or training "serious game in health". During the afternoon was held the second edition of the BlueSky Meeting, real catalyst for R&D partnerships. A press conference on the same day by Lyonbiopole, allowing its president, Philippe Archinard and its director, Florence Agostino-Etchetto, to present the cluster 3.0 strategy and give the floor to five project leaders.
Contact: Claudia Chagneau, R&D Projects Manager -

Learn more

10/04/2013 - Lyonbiopole signs its performance contract and officially launches its 3.0 strategy

On the occasion of the presentation of the Regional Innovation Strategy at the "Hotel de Region" on October 4th, the cluster signed his agreement performance contract for 2013 to 2018. Lyonbiopole thus undertakes to follow the strategic roadmap 3.0 described in this performance contract in order to achieve the following goals products, services and marketing, while deploying an action plan with indicators. Lyonbiopole intends to position itself as the coordinator of the Rhône-Alpes health sector by gradually expanding its scope to new issues in health in order to address major challenges for patient's benefit.
Contact: Florence Agostino-Etchetto, General Manager -

iDD biotech

iDD biotech Lyonbiopole's member, specializing in R&D dedicated to the development of novel therapeutic antibodies, has successfully completed its first external financing round worth around 1.5 million euros. This first round finalized with a group of private investors from the pharmaceutical industry reinforces the investments already made by the incumbent shareholders to enhance its library of monoclonal antibodies. The arrival of these new investors, from the R&D and pharmaceutical, biotech allows iDD to finalize the regulatory preclinical development and to prepare for its portfolio of projects, the entry into clinical trials.

Learn more

11/26/2013 - H2020 – Health projects information day in Lyon

The National Contact Points of the new European Programme Horizon 2020 organize in collaboration with Lyonbiopole, University Claude Bernard Lyon 1 and HCL an info day dedicated to the presentation of H2020 and specific tools for health projects. It will be held on November 26th on La Doua Campus Lyon. Thus, the societal challenge "Health, demographic change and well-being" will be presented in detail, as well as IMI2, EDCTP2. The afternoon will be devoted to individual meetings with health NCP.
Contact: Emilie Romeo, Project manager -

Learn more

12/06/2013 - 5th edition of the Lyonbiopole’s Private Inv€stment Day

For the 5th time, Lyonbiopole organizes, in partnership with BPI France, CREALYS, GRAIN and NOVACITE, and with the support of Sanofi Pasteur, the Private Inv€stment Day on Friday, December 6th 2013, from 8.00 am to 3.00 pm at the Sanofi Pasteur's Headquarters (Lyon, Gerland). This event, dedicated to SMBs and private investors aims to foster interactions between companies, new entrepreneurs and investors of every kind. This day will be organized around moments of networking (roundtables, testimony and breaks) and company and project presentations.
Contact : kevin Romani, Director SMEs Developement -

Learn more

12/13/2013 - 5th edition of Hospital Acquired Infections Day

Lyonbiopole and Finovi Foundation organize the 5th edition of Hospital Acquired Infections Day on december 13th 2013, at the "Institut Français de l’Education", Lyon 7. As part of this edition, entitled "Resistance and Innovation", speakers from the industrial and academic will exchange on issues including effluent and resistance, on innovative approaches in diagnosis of infections, immunotherapy, vaccination and also on the link between antibiotics - antifungal and microbial stress.
Contact :  Sarah Crochon - Innovation Project Manage - Sepsis Program -

Learn more

02/11/2014 - Save the date - INRIA Industry meeting!

On February 11th 2014, INRIA, in partnership with Lyonbiopole, is organizing in Lyon an INRIA-Industry meeting, dedicated to the role of modeling and data analysis and management in the conception of new drugs and healthcare products.
Speakers from industry, academia and healthcare professionals will share their experience and provide an overview. Demos from INRIA teams and other Lyonbiopole members will be on display in the showroom. Bioinformatics, "omics" data analysis, bio-modeling, HPC and Big-Data will be among the addressed topics.
Contact: Claudia Chagneau, R&D Projects Manager  -

Learn more

BIO-Europe 2013
November 4th to 6th, 2013, Vienna - Austria
First National Conference on Vaccine
November 7th 2013, Lyon - France
EU-Russia - Common Interests in Biotechnology
November 12th to 15th 2013, Turku - Finland
Translational Research in Chronic Viral Hepatitis
November 29th and 30th 2013 - Lyon - France
Business mission: Meet the Irish & British Biotechs
December 10th  to 12th  2013, Dublin - Ireland / London - United Kingdom
Genesis 2013
December 12th 2013, London - United Kingdom
Bio-Europe Spring 2014
March 10th to 12 th 2014, Turino - Italia
BIO 2014
June 23th to 26th 2014, San Diego - US
10/2013 - The 10th IMI call for project open

The IMI programme has just launched in October, its 10th call for projects dedicated to infectious disease and  in particular to: « Immunological assay standardization and development for use in assessments of correlates of protection for influenza vaccines ».  Several webinars will be organised: The deadline for submission is on January 28, 2014. Lyonbiopole offers you to benefit from its ETTP program and to assist you in setting up your European projects.
Contact: Emilie Romeo, Project Manager -

Learn more

10/2013 - New Eurostars 2 call for projects

After the success of the 1st Eurostars programme, the EC launches Eurostars 2. This funding programme is fully dedicated to innovative SMEs aiming to launch R&D projects closed to the market, that are collaborative and European (at least 2 partners from EU). The funding rate for projects goes from 30 to 40%. Thus the new Eurostars 2 call for project is launched, which submission deadline is planned on March 13, 2014. Lyonbiopole supports you for EU project set-up thanks to its ETP programme.
Contact: Emilie Romeo - Project Manager -

Learn more

10/17/2013 - Successful networking mission between BioWin and Lyonbiopole

This networking day took place in BioWin headquarters in Charleroi and welcomed 36 participants: 26 Walloon representatives and 10 from Rhône-Alpes. BioWin and Lyonbiopole first highlighted their complementarity in the Immunology, Diagnostic in vitro, cell therapy and regenerative medicine areas. Then a representative of the DG06 presented funding opportunities for collaborative R&D cross-border projects. Finally, 75  involved companies benefited individual appointments.
Contact: Kevin Romani, Director SMEs Development -

10/11/2013 - Output of the first Collaborative R&D projects Directory

During the 7th edition of its Partnering Days, Lyonbiopole presented to all participants its firts Collaborative R&D projects Directory. It identifies 155 collaborative projects approved by the cluster or supported by the Cancer Research Center - CLARA -  of which 77 completed projects and 78 ongoing projects. Thus, there are 32 projects in in vitro diagnostic, 12 in veterinary medicine 36 in medical technology and 105 in human medicine. If you wish to receive an electronic version will be available soon.
Contact: Claudia Chagneau, R&D Projects Manager -

10/11/2013 - The BlueSky Meeting: a real accelerator of strategic public/private partnerships in health

On the occasion of the 7th edition of its Partnering Days which was attended by over 300 people, Lyonbiopole has strengthened the partnership dynamic of the event by including the second edition of its BlueSky Meeting. Designed as a catalyst for R&D partnerships, this new program offered the opportunity to discover many projects and innovative technologies from the Rhône-Alpes ecosystem but also to get to know the open innovation strategies and collaborations thematics of three major players in health BIOASTER, Sanofi and Roche.
Contact : Sarah Crochon,  Innovation Project Manager – Sepsis Program,

09/25 to 27/2013 - Lyonbiopole, Alsace BioValley and CQDM launch the 2nd joint call of projects

Lyonbiopole, the Quebec Consortium for Drug Discovery (CQDM) and Alsace BioValley were pleased to launch at the Sherbrooke International Life Sciences Summit (26-27th september, Sherbrooke, Quebec) their second call for proposals within their joint program. This call aims to fund projects for the development of innovative technologies with a strong and immediate impact on the drug discovery and/or development process.
Contact : Sarah Crochon,  Innovation Project Manager – Sepsis Program,

Learn more

09/26/2013 - The EDCA met on the occasion of  EIC 2013 in Montpellier

The EDCA (European Diagnostic Cluster Alliance) board met during the EIC 2013, dedicated to the in vitro diagnotics on September 25th & 26th in Montpellier. On this occasion, the European partners including Eurobiomed, Biowin and Upssala Bio, reiterated the importance of supporting in vitro diagnostics SMEs at the European level, in particular on the regulatory side. One of the challenges ahead for the alliance will be to directly involve SMEs in the committee's work and identify key issues around the in vitro diagnostics to set up projects in Horizon 2020.
Contact : Emilie Romeo, Project Manager -

Learn more

09/17/2013 - MabDesign project, led by Lyonbiopole for the French industrial sector of the therapeutic antibody, retained

MabDesign project was selected through calls for "STRATEGIC INDUSTRIAL SECTORS" projects. Lead and coordinated by Lyonbiopole, it aims to organize the national industrial sector of therapeutic antibodies, to enhance the competitiveness of all its stakeholders and to gather a dense network of innovative SMEs in the region. The project will be financed up to nearly 2 million by BPI France.

10/18/2013 - Valneva Wins FDA Market Exclusivity for the Pediatric Indication of IXIARO® in the United States

Following approval by the U.S. Food and Drug Administration (FDA) of the pediatrie indication for Valneva's Japanese encephalitis vaccine IXIARO® in May 2013, the vaccine has now been also granted orphan drug market exclusivity by FDA.

Learn more

10/16/2013 - Imaxio sells its genomics division to Hybrigenics to focus on its immunology business

Imaxio will focus more on its immunology R&D operations. The work is based on proprietary IMX313 antigen re-engineering technology, which aims to create a significant improvement in the immunogenicity and therefore the effectiveness of each vaccine in which it is used.

Learn more

10/07/2013 - Poxel's Anti-diabetic Imeglimin Confirms Its Unique Mechanism of Action in Type 2 Diabetic Patients

Poxel SA, announced that Imeglimin, a novel compound in development to treat Type 2 diabetes, increases insulin secretion in response to glucose, confirming previous preclinical and clinical results.

Learn more

09/24/2013 - Fluoptics raises € 2 million

Half of this financing is provided by the original investors, Rhône-Alpes region Business Angels and the viaduc participations regional fund. The 2nd half is financed by a new investor, the Angel source fund, managed by iSource.This round follows a first round boot to made of 750 K€ in 2010. It will enable Fluoptics further developments and start marketing its Fluobeam ® fluorescence imaging system for many clinical applications, after obtaining medical CE marking.

09/13/2013 – Appointment of Tom Shepherd as BIOASTER Chief Executive Officer

The Board of Directors of BIOASTER, announced the appointment of Tom Shepherd as Chief Executive Office. He succeeds to Jacques Berger who, following his retirement from his previous position as Directeur Général Délégué of Sanofi Pasteur, had been asked to set up BIOASTER’s corporate and laboratory operations and establish the foundations for its future growth into a leading research institute. Tom SHEPHERD took up his post in Lyon September 2nd, 2013.

Learn more

© Lyonbiopole 2021  |  CREDITS  |  LEGAL NOTICE  |